GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH

Дата публикации: 27-04-2026 12:00:00

Designations recognise potential for efimosfermin to address significant unmet medical need & reflect momentum in GSKs liver health pipeline

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA	0	6.94	28-04-2026
2	GSK presents data from its advancing liver pipeline at AASLD 2025	0	14.22	07-11-2025
3	GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B	0	19.82	07-01-2026
4	GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	0	9.8	11-05-2026
5	Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B	0	14.39	27-03-2026
6	Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B	0	12.98	30-03-2026
7	Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B	0	10.98	26-02-2026
8	Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B	0	7.23	24-08-2026
9	Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)	0	7.95	19-03-2026
10	GSK enters agreement to acquire 35Pharma Inc.	0	18.7	25-02-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.94. Источник: www.gsk.com.